Multiple sclerosis: Genetics, biomarkers, treatments

Current Opinion in Neurology

Volumn 29, Issue 3, 2016, Pages 345-353

  Axisa, Pierre Paul ^a,b,c,d   Hafler, David A ^a,e  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CNRS   (France)

^c University of Toulouse III   (France)

^d INSERM   (France)

^e BROAD INSTITUTE OF MIT AND HARVARD   (United States)

Author keywords

autoimmunity; biomarkers; genome wide association study; multiple sclerosis; natalizumab

Indexed keywords

BIOLOGICAL MARKER; FINGOLIMOD; NATALIZUMAB; IMMUNOLOGIC FACTOR;

DISEASE COURSE; GENETIC ANALYSIS; GENOME-WIDE ASSOCIATION STUDY; HUMAN; IMMUNOLOGY; IMMUNOPATHOLOGY; MULTIPLE SCLEROSIS; NONHUMAN; REVIEW; TREATMENT RESPONSE; DISEASE EXACERBATION; GENETIC PREDISPOSITION; GENETICS;

BIOMARKERS; DISEASE PROGRESSION; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; IMMUNOLOGIC FACTORS; MULTIPLE SCLEROSIS;

EID: 84964033731     PISSN: 13507540     EISSN: 14736551     Source Type: Journal    
DOI: 10.1097/WCO.0000000000000319     Document Type: Review

References (144)

1. Nylander A, Hafler DA. Multiple sclerosis. Journal of Clinical Investigation 2012; 122:1180-1188.
2. Tishkoff SA, Verrelli BC. Role of evolutionary history on haplotype block structure in the human genome: implications for disease mapping. Curr Opin Genet Dev 2003; 13:569-575.
3. Frazer KA, Ballinger DG, Cox DR, et al. A second generation human haplotype map of over 3.1 million SNPs. Nature 2007; 449:851-861.
4. Hindorff LA, Sethupathy P, Junkins HA, et al. Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. Proc Natl Acad Sci USA 2009; 106:9362-9367.
5. Welter D, MacArthur J, Morales J, et al. The NHGRI GWAS Catalog, a curated resource of SNP-trait associations. Nucleic Acids Res 2013; 42 (D1):D1001-D1006.
6. International Multiple Sclerosis Genetics C. Hafler DA, Compston A, et al. Risk alleles for multiple sclerosis identified by a genomewide study. New Engl J Med 2007; 357:851-862.
7. Australia, New Zealand Multiple Sclerosis Genetics Consortium (ANZgene). Genome-wide association study identifies new multiple sclerosis susceptibility loci on chromosomes 12 and 20. Nat Genet 2009; 41:824-828.
8. Burton PR, Clayton DG, Cardon LR, et al. Association scan of 14 500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat Genet 2007; 39:1329-1337.
9. Comabella M, Craig DW, Camin a-Tato M, et al. Identification of a novel risk locus for multiple sclerosis at 13q31.3 by a pooled genome-wide scan of 500 000 single nucleotide polymorphisms. PLoS One 2008; 3:e3490.
10. Baranzini SE, Wang J, Gibson RA, et al. Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. Human Molecular Genetics 2008; 18:767-778.
11. Jakkula E, Leppä V, Sulonen A-M, et al. Genome-wide association study in a high-risk isolate for multiple sclerosis reveals associated variants in STAT3 gene. Am J Human Genet 2010; 86:285-291.
12. Sanna S, Pitzalis M, Zoledziewska M, et al. Variants within the immunor-egulatory CBLB gene are associated with multiple sclerosis. Nat Genet 2010; 42:495-497.
13. Aulchenko YS, Hoppenbrouwers IA, Ramagopalan SV, et al. Genetic variation in the KIF1B locus influences susceptibility to multiple sclerosis. Nat Genet 2008; 40:1402-1403.
14. Nischwitz S, Cepok S, Kroner A, et al. Evidence for VAV2 and ZNF433 as susceptibility genes for multiple sclerosis. J Neuroimmunol 2010; 227 (1-2): 162-166.
15. De Jager PL, Jia X, Wang J, et al. Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. Nat Genet 2009; 41:776-782.
16. International Multiple Sclerosis Genetics, Consortium, Wellcome Trust Case Control Consortium 2, Sawcer S, et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011; 476:214-219.
17. Cozen W, Li D, Best T, et al. A genome-wide meta-analysis of nodular sclerosing Hodgkin lymphoma identifies risk loci at 6p21.32. Blood 2011; 119:469-475.
18. International Multiple Sclerosis Genetics Consortium, Beecham AH, Patso-poulos NA, et al. Analysisofimmune-related loci identifies48 new susceptibility variants for multiple sclerosis. Nat Genet 2013; 45:1353-1360.
19. Hunt KA, Smyth DJ, Balschun T, et al. Rare and functional SIAE variants are not associated with autoimmune disease risk in up to 66 924 individuals of European ancestry. Nat Genet 2011; 44:3-5.
20. Farh KK-H, Marson A, Zhu J, et al. Genetic and epigenetic fine mapping of causal autoimmune disease variants. Nature 2014; 518:337-343.
21. Genomes Project C, Abecasis GR, Auton A, et al. An integrated map of genetic variation from 1092 human genomes. Nature 2012; 491:56-65.
22. Viglietta V. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med 2004; 199:971-979.
23. Haas J, Hug A, Viehover A, et al. Reduced suppressive effect of CD4+CD25high regulatory T cells on the T cell immune response against myelin oligodendrocyte glycoprotein in patients with multiple sclerosis. Eur J Immunol 2005; 35:3343-3352.
24. Koenen HJPM, Smeets RL, Vink PM, et al. Human CD25highFoxp3pos regulatory T cells differentiate into IL-17-producing cells. Blood 2008; 112:2340-2352.
25. Beriou G, Costantino CM, Ashley CW, et al. IL-1 7-producing human peripheral regulatory T cells retain suppressive function. Blood 2009; 113:4240-4249.
26. Ayyoub M, Deknuydt F, Raimbaud I, et al. Human memory FOXP3+ Tregs secrete IL-17 ex vivo and constitutively express the TH17 lineage-specific transcription factor RORyt. Proc Natl Acad Sci USA 2009; 106:8635-8640.
27. Dominguez-Villar M, Baecher-Allan CM, Hafler DA. Identification of T helper type 1-like, Foxp3+ regulatory T cells in human autoimmune disease. Nat Med 2011; 17:673-675.
28. Schneider A, Long SA, Cerosaletti K, et al. In active relapsing-remitting multiple sclerosis, effector T cell resistance to adaptive Tregs involves IL-6-mediated signaling. Sci Transl Med 2013; 5:170ra15-215ra.
29. Housley WJ, Fernandez SD, Vera K, et al. Genetic variants associated with autoimmunity drive NF B signaling and responses to inflammatory stimuli. Sci Transl Med 2015; 7:291ra93.
30. Sarnico I, Lanzillotta A, Benarese M, et al. NF-kappaBdimers in the regulation of neuronal survival. Int Rev Neurobiol 2009; 85:351-362.
31. Goris A, Pauwels I, Gustavsen MW, et al. Genetic variants are major determinants of CSF antibody levels in multiple sclerosis. Brain 2015; 138:632-643.
32. Buck D, Albrecht E, Aslam M, et al. Genetic variants in the immunoglobulin heavy chain locus are associated with the IgG index in multiple sclerosis. Ann Neurol 2012; 73:86-94.
33. Idiman E, Ozakbas S, Dogan Y, Kosehasanogullari G. The significance of oligoclonal bands in multiple sclerosis: Relevance of demographic and clinical features, and immunogenetic backgrounds. J Neuroimmunol 2009; 212 (1-2):121-124.
34. Imrell K, Landtblom AM, Hillert J, Masterman T. Multiple sclerosis with and without CSF bands: Clinically indistinguishable but immunogenetically distinct. Neurology 2006; 67:1062-1064.
35. Kikuchi S, Fukazawa T, Niino M, et al. HLA-related subpopulations of MS in Japanese with and without oligoclonal IgG bands. Neurology 2003; 60:647-651.
36. Leone MA, Barizzone N, Esposito F, et al. Association of genetic markers with CSF oligoclonal bands in multiple sclerosis patients. PLoS One 2013; 8:e64408.
37. Romero-Pinel L, Martinez-Yelamos S, Bau L, et al. Association of HLA-DRB1 ∗15 allele and CSF oligoclonal bands in a Spanish multiple sclerosis cohort. Eur J Neurol 2011; 18:1258-1262.
38. Yoshimura S, Isobe N, Matsushita T, et al. Genetic and infectious profiles influence cerebrospinal fluid IgG abnormality in Japanese multiple sclerosis patients. PLoS One 2014; 9:e95367.
39. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50:121-127.
40. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011; 69:292-302.
41. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the 'McDonald Criteria'. Ann Neurol 2005; 58:840-846.
42. Miller D, Barkhof F, Montalban X, et al. Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis. Lancet Neurol 2005; 4:281-288.
43. Gunnarsson M, Malmestrom C, Axelsson M, et al. Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab. Ann Neurol 2010; 69:83-89.
44. Jones JL, Anderson JM, Phuah CL, et al. Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity. Brain 2010; 133:2232-2247.
45. Yahr MD, Goldensohn SS, Kabat EA. Further studies on the gamma globulin content of cerebrospinal fluid in multiple sclerosis and other neurological diseases. Ann N Y Acad Sci 1954; 58:613-624.
46. Lowenthal A, Vansande M, Karcher D. The differential diagnosis of neurological diseases by fractionating electrophoretically the CSF gamma-globulins. J Neurochem 1960; 6:51-56.
47. Ignacio RJ, Liliana P, Edgardo C. Oligoclonal bands and MRI in clinically isolated syndromes: predicting conversion time to multiple sclerosis. J Neurol 2010; 257:1188-1191.
48. Kuhle J, Disanto G, Dobson R, et al. Conversion from clinically isolated syndrome to multiple sclerosis: a large multicentre study. Mult Scler 2015; 21:1013-1024.
49. Stangel M, Fredrikson S, Meinl E, et al. The utility of cerebrospinal fluid analysis in patients with multiple sclerosis. Nat Rev Neurol 2013; 9:267-276.
50. Barkhof F. MRI in multiple sclerosis: correlation with expanded disability status scale (EDSS). Mult Scler 1999; 5:283-286.
51. Fisniku LK, Brex PA, Altmann DR, et al. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain 2008; 131:808-817.
52. Zivadinov R, Leist TP. Clinical magnetic resonance imaging correlations in multiple sclerosis. J Neuroimaging 2005; 15:10S-21S.
53. Li DKB, Held U, Petkau J, et al. MRI T2 lesion burden in multiple sclerosis: a plateauing relationship with clinical disability. Neurology 2006; 66:1384-1389.
54. Bruck W, Bitsch A, Kolenda H, et al. Inflammatory central nervous system demyelination: correlation of magnetic resonance imaging findings with lesion pathology. Ann Neurol 1997; 42:783-793.
55. Katz D, Taubenberger JK, Cannella B, et al. Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis. Ann Neurol 1993; 34:661-669.
56. Khoury SJ, Guttmann CRG, Orav EJ, et al. Longitudinal MRI in multiple sclerosis: correlation between disability and lesion burden. Neurology 1994; 44:2120-2124.
57. Smith ME, Stone LA, Albert PS, et al. Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentetate dimeglu-mine-enhancing magnetic resonance imaging lesions. Ann Neurol 1993; 33:480-489.
58. Rocca MA, Amato MP, De Stefano N, et al. Clinical and imaging assessment of cognitive dysfunction in multiple sclerosis. Lancet Neurol 2015; 14:302-317.
59. Geurts JJG, Calabrese M, Fisher E, Rudick RA. Measurement and clinical effect of grey matter pathology in multiple sclerosis. Lancet Neurol 2012; 11:1082-1092.
60. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. New Engl J Med 2006; 354:899-910.
61. Antoniol C, Stankoff B. Immunological markers for PML prediction in MS patients treated with natalizumab. Front Immunol 2015; 5:668.
62. Outteryck O, Zephir H, Salleron J, et al. JC-virus seroconversion in multiple sclerosis patients receiving natalizumab. Mult Scler J 2013; 20:822-829.
63. Olsson T, Achiron A, Alfredsson L, et al. Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort. Mult Scler J 2013; 19:1533-1538.
64. Plavina T, Subramanyam M, Bloomgren G, et al. Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol 2014; 76:802-812.
65. Krishnamoorthy G, Saxena A, Mars LT, et al. Myelin-specific T cells also recognize neuronal autoantigen in a transgenic mouse model of multiple sclerosis. Nat Med 2009; 15:626-632.
66. Ramadan A, Lucca LE, Carrié N, et al. In situ expansion of T cells that recognize distinct self-antigens sustains autoimmunity in the central nervous system. Brain 2016. [Epub ahead of print]
67. Kuhle J, Malmeström C, Axelsson M, et al. Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis. Acta Neurologica Scandinavica 2013; 128:e33-e36.
68. Bielekova B, McDermott MP. Will CSF biomarkers guide future therapeutic decisions in multiple sclerosis? Neurology 2015; 84:1620-1621.
69. Disanto G, Adiutori R, Dobson R, et al. Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome. J Neurol Neurosurg Psychiatry 2015; 86:273-279.
70. Salzer J, Svenningsson A, Sundstrom P. Neurofilament light as a prognostic marker in multiple sclerosis. Mult Scler J 2010; 16:287-292.
71. Modvig S, Degn M, Roed H, et al. Cerebrospinal fluid levels of chitinase 3-like 1 and neurofilament light chain predict multiple sclerosis development and disability after optic neuritis. Mult Scler J 2015; 21:1761-1770.
72. Martinez MAM, Olsson B, Bau L, et al. Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosis. Mult Scler J 2015; 21:550-561.
73. Kuhle J, Disanto G, Lorscheider J, et al. Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis. Neurology 2015; 84:1639-1643.
74. Romme Christensen J, Ratzer R, Bornsen L, et al. Natalizumab in progressive MS: Results of an open-label, phase 2A, proof-of-concept trial. Neurology 2014; 82:1499-1507.
75. Petzold A. Markers for different glial cell responses in multiple sclerosis: clinical and pathological correlations. Brain 2002; 125:1462-1473.
76. Cohen SR, Herndon RM, McKhann GM. Radioimmunoassay of myelin basic protein in spinal fluid. New Engl J Med 1976; 295:1455-1457.
77. Whitaker JN. Myelin encephalitogenic protein fragments in cerebrospinal fluid of persons with multiple sclerosis. Neurology 1977; 27:911-920.
78. Avsar T, Korkmaz D, Tutuncu M, et al. Protein biomarkers for multiple sclerosis: semi-quantitative analysis of cerebrospinal fluid candidate protein biomarkers in different forms of multiple sclerosis. Mult Scler J 2012; 18:1081-1091.
79. Massaro AR, Tonali P. Cerebrospinal fluid markers in multiple sclerosis: an overview. Mult Scler 1998; 4:1-4.
80. Davis BH, Zarev PV. Human monocyte CD163 expression inversely correlates with soluble CD163 plasma levels. Cytometry 2004; 63B:16-22.
81. Stilund M, Reuschlein A-K, Christensen T, et al. Soluble CD163 as a marker of macrophage activity in newly diagnosed patients with multiple sclerosis. PLoS One 2014; 9:e98588.
82. Fabriek BO, Møller HJ, Vloet RPM, et al. Proteolytic shedding of the macro-phage scavenger receptor CD163 in multiple sclerosis. J Neuroimmunol 2007; 187 (1-2):179-186.
83. Stilund M, Gjelstrup MC, Petersen T, et al. Biomarkers of inflammation and axonal degeneration/damage in patients with newly diagnosed multiple sclerosis: contributions of the soluble CD163 CSF/serum ratio to a bio-marker panel. PLoS One 2015; 10:e0119681.
84. Canto E, Tintore M, Villar LM, et al. Chitinase 3-like 1: prognostic biomarker in clinically isolated syndromes. Brain 2015; 138:918-931.
85. Peltomaa R, Paimela L, Harvey S, et al. Increased level of YKL-40 in sera from patients with early rheumatoid arthritis: a new marker for disease activity. Rheumatol Int 2001; 20:192-196.
86. Vos K. Raised human cartilage glycoprotein-39 plasma levels in patients with rheumatoid arthritis and other inflammatory conditions. Ann Rheum Dis 2000; 59:544-548.
87. Vind I, Johansen JS, Price PA, Munkholm P. Serum YKL-40, a potential new marker of disease activity in patients with inflammatory bowel disease. Scand J Gastroenterol 2003; 38:599-605.
88. Comabella M, Fernandez M, Martin R, et al. Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis. Brain 2010; 133:1082-1093.
89. Chabas D. The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science 2001; 294:1731-1735.
90. Sinclair C, Mirakhur M, Kirk J, et al. Up-regulation of osteopontin and alphaBeta-crystallin in the normal-appearing white matter of multiple sclerosis: an immunohistochemical study utilizing tissue microarrays. Neuropathol Appl Neurobiol 2005; 31:292-303.
91. Comabella M, Pericot I, Goertsches R, et al. Plasma osteopontin levels in multiple sclerosis. J Neuroimmunol 2005; 158 (1-2):231-239.
92. Szalardy L, Zadori D, Simu M, et al. Evaluating biomarkers of neuronal degeneration and neuroinflammation in CSF of patients with multiple sclero-sis-osteopontin as a potential marker of clinical severity. J Neurol Sci 2013; 331 (1-2):38-42.
93. Vogt MHJ, Floris S, Killestein J, et al. Osteopontin levels and increased disease activity in relapsing-remitting multiple sclerosis patients. J Neuroim-munol 2004; 155 (1-2):155-160.
94. Vogt MHJ, Lopatinskaya L, Smits M, et al. Elevated osteopontin levels in active relapsing-remitting multiple sclerosis. Ann Neurol 2003; 53:819-822.
95. Wen S-R, Liu G-J, Feng R-N, et al. Increased levels of IL-23 and osteopontin in serum and cerebrospinal fluid of multiple sclerosis patients. J Neuroim-munol 2012; 244 (1-2):94-96.
96. Bornsen L, Khademi M, Olsson T, et al. Osteopontin concentrations are increased in cerebrospinal fluid during attacks of multiple sclerosis. Mult Scler J 2010; 17:32-42.
97. Kivisakk P, Healy BC, Francois K, et al. Evaluation of circulating osteopontin levels in an unselected cohort of patients with multiple sclerosis: relevance for biomarker development. Mult Scler J 2013; 20:438-444.
98. Runia TF, van Meurs M, Nasserinejad K, Hintzen RQ. No evidence for an association of osteopontin plasma levels with disease activity in multiple sclerosis. Mult Scler J 2014; 20:1670-1671.
99. Martin R. A myelin basic protein peptide is recognized by cytotoxic T cells in the context of four HLA-DR types associated with multiple sclerosis. J Exp Med 1991; 173:19-24.
100. Ota K, Matsui M, Milford EL, et al. T-cell recognition of an immuno-dominant myelin basic protein epitope in multiple sclerosis. Nature 1990; 346:183-187.
101. Pette M, Fujita K, Kitze B, et al. Myelin basic protein-specific T lymphocyte lines from MS patients and healthy individuals. Neurology 1990; 40:1770-1776.
102. Raddassi K, Kent SC, Yang J, et al. Increased frequencies of myelin oligodendrocyte glycoprotein/MHC class II-binding CD4 cells in patients with multiple sclerosis. J Immunol 2011; 187:1039-1046.
103. Cao Y, Goods BA, Raddassi K, et al. Functional inflammatory profiles distinguish myelin-reactive T cells from patients with multiple sclerosis. Sci Transl Med 2015; 7:287ra74-374ra.
104. Hauser SL, Dawson DM, Lehrich JR, et al. Intensive immuno-suppression in progressive multiple sclerosis. New Engl J Med 1983; 308:173-180.
105. Paty DW, Li DKB. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43:662-667.
106. Trojano M, Pellegrini F, Fuiani A, et al. New natural history of interferon-b-treated relapsing multiple sclerosis. Ann Neurol 2007; 61:300-306.
107. Trojano M, Pellegrini F, Paolicelli D, et al. Real-life impact of early interferon therapy in relapsing multiple sclerosis. Ann Neurol 2009; 66:513-520.
108. Scalfari A, Knappertz V, Cutter G, et al. Mortality in patients with multiple sclerosis. Neurology 2013; 81:184-192.
109. Goodin DS, Reder AT, Ebers GC, et al. Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFN-1b trial. Neurology 2012; 78:1315-1322.
110. Bermel RA, You X, Foulds P, et al. Predictors of long-term outcome in multiple sclerosis patients treated with interferon beta. Ann Neurol 2013; 73:95-103.
111. Prosperini L, Gallo V, Petsas N, et al. One-year MRI scan predicts clinical response to interferon beta in multiple sclerosis. Eur J Neurol 2009; 16:1202-1209.
112. Kuhle J, Hardmeier M, Disanto G, et al. A 10-year follow-up of the European multicenter trial of interferon beta-1b in secondary-progressive multiple sclerosis. Mult Scler 2016; 22:533-543.
113. McGraw CA, Lublin FD. Interferon beta and glatiramer acetate therapy. Neurotherapeutics 2013; 10:2-18.
114. Borden EC, Sen GC, Uze G, et al. Interferons at age 50: past, current and future impact on biomedicine. Nat Rev Drug Disc 2007; 6:975-990.
115. Comabella M, Lunemann JD, Rio J, et al. A type I interferon signature in monocytes is associated with poor response to interferon-beta in multiple sclerosis. Brain 2009; 132:3353-3365.
116. Ottoboni L, Keenan BT, Tamayo P, et al. An RNA profile identifies two subsets of multiple sclerosis patients differing in disease activity. Sci Transl Med 2012; 4:153ra31-231ra.
117. Brown BA. Natalizumab in the treatment of multiple sclerosis. Ther Clin Risk Manag 2009; 5:585-594.
118. Ransohoff RM. Natalizumab for multiple sclerosis. New Engl J Med 2007; 356:2622-2629.
119. Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. New Engl J Med 2006; 354:911-923.
120. Langer-Gould A, Atlas SW, Green AJ, et al. Progressive multifocal leukoen-cephalopathy in a patient treated with natalizumab. New Engl J Med 2005; 353:375-381.
121. Yousry TA, Major EO, Ryschkewitsch C, et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. New Engl J Med 2006; 354:924-933.
122. Ransohoff RM. PML risk and natalizumab: more questions than answers. Lancet Neurol 2010; 9:231-233.
123. Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab-asso-ciated progressive multifocal leukoencephalopathy. New Engl J Med 2012; 366:1870-1880.
124. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. New Engl J Med 2010; 362:402-415.
125. Kappos L, Radue EW, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. New Engl J Med 2010; 362:387-401.
126. Pelletier D, Hafler DA. Fingolimod for multiple sclerosis. New Engl J Med 2012; 366:339-347.
127. He A, Spelman T, Jokubaitis V, et al. Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis. JAMA Neurol 2015; 72:405-413.
128. Arvin AM, Wolinsky JS, Kappos L, et al. Varicella-zoster virus infections in patients treated with fingolimod. JAMA Neurol 2015; 72:31-39.
129. Lublin F, Miller DH, Freedman MS, et al. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet 2016; 387:1075-1084.
130. Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. New Engl J Med 2012; 367:1098-1107.
131. Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. New Engl J Med 2012; 367:1087-1097.
132. Kappos L, Gold R, Miller DH, et al. Effect of BG-12 on contrast-enhanced lesions in patients with relapsing-remitting multiple sclerosis: subgroup analyses from the phase 2b study. Mult Scler J 2011; 18:314-321.
133. Kappos L, Gold R, Miller DH, et al. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 2008; 372:1463-1472.
134. Cohen JA, Coles AJ, Arnold DL, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 2012; 380:1819-1828.
135. Coles AJ, Twyman CL, Arnold DL, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 2012; 380:1829-1839.
136. Investigators CT, Coles AJ, Compston DA, et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. New Engl J Med 2008; 359:1786-1801.
137. Comi G, Jeffery D, Kappos L, et al. Placebo-controlled trial of oral laquinimod for multiple sclerosis. New Engl J Med 2012; 366:1000-1009.
138. Comi G, Pulizzi A, Rovaris M, et al. Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 2008; 371:2085-2092.
139. Gold R, Giovannoni G, Selmaj K, et al. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. Lancet 2013; 381:2167-2175.
140. Wynn D, Kaufman M, Montalban X, et al. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta. Lancet Neurol 2010; 9:381-390.
141. Bielekova B, Richert N, Howard T, et al. Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. Proc Natl Acad Sci USA 2004; 101:8705-8708.
142. Kappos L, Wiendl H, Selmaj K, et al. Daclizumab HYP versus interferon beta-1a in relapsing multiple sclerosis. New Engl J Med 2015; 373:1418-1428.
143. Media release from Roche on ocrelizumab phase III trials. 2015. Available from: http://www.roche.com/media/store/releases/med-cor-2015-10-08.htm.
144. Montalban X, Hemmer B, Rammohan K, et al. Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis-results of the placebo-controlled, double-blind, Phase III ORATORIO study. ECTRIMS Online Library 2015.